Teriparatide increases the maturation of circulating osteoblast precursors

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

The aim of this study was to investigate the effect of teriparatide on circulating OB precursors.

Why It Was Studied

This study shows that teriparatide promotes the circulating osteoblast (OB) precursor degree of maturation in patients affected by postmenopausal osteoporosis.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, women only.

The researchers evaluated by flow cytometry and real-time PCR the expression of OBs typical markers in peripheral blood mononuclear cells during treatment with teriparatide plus calcium and vitamin D, raloxifene plus calcium and vitamin D or calcium and vitamin D alone at various time points.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Serum bone alkaline phosphatase and osteocalcin (OC) were measured as markers of bone turnover.

What Was Measured

PubMed files the paper under topics including Alkaline Phosphatase, Biomarkers, Bone Density Conservation Agents, Calcium, Cell Differentiation, Mesenchymal Stem Cells and Osteoblasts.

What This Means in Plain Language

The paper is a randomized study of Teriparatide.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.